Novavax Joint Venture Builds Vaccine Factory
June 14, 2010
According to the Associated Press, drug developer Novavax Inc. said its joint venture with an Indian company has finished building a factory in Dholka, India, that will produce flu vaccines. CPL Biologicals plans to start equipment and installation validation this month. The factory will produce up to 60 million doses of new vaccines every year. Novavax, which is based in Rockville, Md., said it will produce seasonal and pandemic flu vaccines using technology that enables rapid vaccine development without the use of live virus. CPL Biologicals is a joint venture of Novavax and Cadila Pharmaceuticals Ltd., a privately held drug company.